Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention

被引：0
|
作者：
Kertesz, Stefan G. [1 ]
Satel, Sally L. [2 ]
DeMicco, James [3 ]
Dart, Richard C. [4 ]
Alford, Daniel P. [5 ,6 ]
机构：
[1] Univ Alabama Birmingham, Sch Med, Birmingham Vet Affairs Med Ctr, 1717 11th Ave South,MT608, Birmingham, AL 35205 USA
[2] Yale Univ, Sch Med, Amer Enterprise Inst, Washington, DC USA
[3] Long Isl Univ, Coll Pharm, Brooklyn, NY USA
[4] Denver Hlth & Hosp Author, Denver, CO USA
[5] Boston Univ, Sch Med, Clin Addict Res & Educ CARE Unit, Boston, MA 02118 USA
[6] Boston Med Ctr, Boston, MA USA
来源：
SUBSTANCE ABUSE | 2019年 / 40卷 / 01期
关键词：
CHRONIC PAIN; OVERDOSE; RISK;
D O I：
10.1080/08897077.2019.1613830
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
引用
收藏
页码：4 / 6
页数：3
相关论文
共 38 条
  • [1] Opioid discontinuation as an institutional mandate: Questions and answers on why we wrote to the Centers for Disease Control and Prevention
    Kertesz, Stefan G.
    Satel, Sally L.
    DeMicco, James
    Dart, Richard C.
    Alford, Daniel P.
    SUBSTANCE ABUSE, 2019, 40 (04) : 466 - 468
  • [2] Intended Target of the Centers for Disease Control and Prevention Opioid Guidelines
    Meghani, Salimah H.
    JAMA ONCOLOGY, 2016, 2 (09) : 1243 - 1243
  • [3] Opioid Prescribing Before and After the Centers for Disease Control and Prevention's 2016 Opioid Guideline
    Delcher, Chris
    Slavova, Svetla
    Wang, Yanning
    Henry, Stephen G.
    ANNALS OF INTERNAL MEDICINE, 2019, 170 (08) : 581 - 582
  • [4] The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused?
    Pergolizzi, J. V., Jr.
    Raffa, R. B.
    LeQuang, J. A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (06) : 592 - 593
  • [5] Why an independent, science-based Centers for Disease Control and Prevention matters
    Blacksin, Beth
    Kneipp, Shawn
    Kelly, Patricia J.
    PUBLIC HEALTH NURSING, 2020, 37 (06) : 819 - 820
  • [6] Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report
    Kroenke, Kurt
    Alford, Daniel P.
    Argoff, Charles
    Canlas, Bernard
    Covington, Edward
    Frank, Joseph W.
    Haake, Karl J.
    Hanling, Steven
    Hooten, W. Michael
    Kertesz, Stefan G.
    Kravitz, Richard L.
    Krebs, Erin E.
    Stanos, Steven P., Jr.
    Sullivan, Mark
    PAIN MEDICINE, 2019, 20 (04) : 724 - 735
  • [7] Opioid Prescribing in the United States Before and After the Centers for Disease Control and Prevention's 2016 Opioid Guideline
    Bohnert, Amy S. B.
    Guy, Gery P., Jr.
    Losby, Jan L.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (06) : 367 - +
  • [8] Why do not surgeons and coworkers strictly follow the Centers for Disease Control and Prevention guidelines?
    Fujita, Tetsuji
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 207 (01) : 140 - 140
  • [9] Tramadol and Opioid Prescription Rates in Chronic Kidney Disease Patients Before and After the 2016 Centers for Disease Control and Prevention Opioid Guideline
    Leja, Noah
    Genord, Cheryl K.
    Berriman, Sarah M.
    Ellis, Jessica J.
    HOSPITAL PHARMACY, 2022, 57 (01) : 101 - 106
  • [10] Re: Challenges with Implementing the Centers for Disease Control and Prevention Opioid Guideline: A Consensus Panel Report
    Scheman, Judith
    PAIN MEDICINE, 2020, 21 (09) : 2005 - 2006
1234